Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival

Marta Rossi; Greta Carioli; Martina Bonifazi; Alberto Zambelli; Matteo Franchi; Lorenzo Moja; Antonella Zambon; Giovanni Corrao; Carlo La Vecchia; Carlo Zocchetti; Eva Negri

doi:10.1016/j.ejca.2015.09.012

Related publications

Article2014

Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: A large cohort study from clinical practice

Martina Bonifazi, Matteo Franchi, Marta Rossi, Alberto Zambelli, Lorenzo Moja, Antonella Zambon, Giovanni Corrao, Carlo La Vecchia, Carlo Zocchetti, Eva Negri

Article2013

Trastuzumab-Related Cardiotoxicity in Early Breast Cancer: A Cohort Study

Martina Bonifazi, Matteo Franchi, Marta Rossi, Lorenzo Moja, Alberto Zambelli, Antonella Zambon, Giovanni Corrao, Carlo La Vecchia, Carlo Zocchetti, Eva Negri

Article2014

Effectiveness of trastuzumab in first-line HER2+ metastatic breast cancer after failure in adjuvant setting: A controlled cohort study.

Eva Negri, Alberto Zambelli, Matteo Franchi, Marta Rossi, Martina Bonifazi, Giovanni Corrao, Antonella Zambon, Lorenzo Moja, Carlo Zocchetti, Carlo La Vecchia

Article2014

Effectiveness of Trastuzumab in First-Line HER2+ Metastatic Breast Cancer After Failure in Adjuvant Setting: A Controlled Cohort Study

Eva Negri, Alberto Zambelli, Matteo Franchi, Marta Rossi, Martina Bonifazi, Giovanni Corrao, Lorenzo Moja, Carlo Zocchetti, Carlo La Vecchia

Article2017

DNA methylation signature to identify trastuzumab response in HER2 breast cancer models

Sònia Palomeras, Ángel Diaz Lagares, Adriana Blancafort, Ariadna Sarrats, A.B. Crujeiras Martinez, Juan Sandoval, Marc Rabionet, Alana L. Welm, Manel Esteller, Teresa Puig

Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival

Discussion(0)

Related publications

Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: A large cohort study from clinical practice

Trastuzumab-Related Cardiotoxicity in Early Breast Cancer: A Cohort Study

Effectiveness of trastuzumab in first-line HER2+ metastatic breast cancer after failure in adjuvant setting: A controlled cohort study.

Effectiveness of Trastuzumab in First-Line HER2+ Metastatic Breast Cancer After Failure in Adjuvant Setting: A Controlled Cohort Study

DNA methylation signature to identify trastuzumab response in HER2 breast cancer models